Skip to main content
NVDA+0.14%AAPL-0.11%GOOGL+1.56%MSFT-0.11%AMZN-0.06%TSM+2.96%SPCX+7.35%META-0.06%AVGO+3.35%TSLA+0.21%SKHY+0.84%MU-0.46%BRK-B+0.43%LLY-0.61%AMD+2.95%JPM-0.24%WMT0.00%ASMLa+3.51%XOM+0.12%V+0.23%JNJ-1.02%INTC-0.56%0700.HK-0.02%MA+0.41%ABBV+1.11%1398.HK-0.23%CSCO+3.16%LRCX+2.17%AMAT+2.03%AP2d+2.88%CVX-0.20%ORCL+3.06%COST+0.62%CAT+2.31%BAC+0.04%DELL+3.82%KO-0.52%PG+0.67%UNH+1.83%0005.HK-0.11%ARM+5.18%HSBA.L+0.36%3988.HK-0.21%GE-0.91%1816.HK-28.01%MS+1.22%0857.HK-0.21%0939.HK-0.58%PM-0.38%1288.HK-0.58%GBPTRY+0.41%GBPHKD+0.32%GBPMXN-0.28%USDILS+0.16%USDCOP-0.04%GBPNZD0.00%GBPSGD0.00%GBPZAR0.00%EURSEK0.00%USDDKK0.00%GBPCHF0.00%GBPUSD0.00%GBPCAD0.00%USDPLN0.00%CHFNOK0.00%EURPLN0.00%PLNJPY0.00%NZDCAD0.00%NZDMXN0.00%EURCAD0.00%CHFJPY0.00%EURUSD0.00%EURJPY0.00%EURNZD0.00%GBPAUD0.00%EURNOK0.00%NZDCHF0.00%NZDSGD0.00%EURCZK0.00%NOKJPY0.00%AUDCAD0.00%CHFSGD0.00%SGDJPY0.00%AUDSGD0.00%NZDUSD0.00%GBPJPY0.00%EURGBP0.00%AUDNZD0.00%AUDJPY0.00%AUDUSD0.00%USDJPY0.00%USDCNH0.00%EURCHF0.00%USDMXN0.00%USDNOK0.00%USDTHB0.00%USDTRY0.00%USDSEK0.00%USDCAD0.00%USDCHF0.00%EURHKD0.00%EURAUD0.00%AUDNOK0.00%EURCNH0.00%EURZAR0.00%EURSGD0.00%AUDDKK0.00%CHFSEK0.00%AUDCHF0.00%USDSGD0.00%CADCHF0.00%NZDJPY0.00%EURDKK0.00%USDZAR0.00%USDHKD0.00%CADJPY0.00%GAGUSD0.00%XAGUSD0.00%HG10.00%S10.00%C10.00%XNGUSD0.00%USOIL0.00%W10.00%XAUUSD0.00%SUGAR0.00%COTTON0.00%COFFEE0.00%BTCUSD+0.37%ETHUSD+7.80%USDTUSD+0.01%XRPUSD+1.02%SOLUSD-0.22%TRXUSDT+0.25%ZECUSDT+0.50%DOGEUSD+0.81%XMRUSDT+1.87%LINKUSD+3.68%XLMUSD+0.04%BCHUSDT+2.11%UNIUSD+1.03%LTCUSD-4.30%SUIUSD+2.81%HBARUSDT-0.95%TONUSD+14.41%TAOUSDT+5.27%AAVEUSD+1.11%DOTUSDT+2.29%ICPUSDT+1.26%WLDUSDT+16.81%ONDOUSDT+0.69%ARBUSDT+2.74%JUPUSDT+4.21%ATOMUSDT+3.33%INJUSDT+1.48%STXUSDT+2.64%FETUSDT+2.06%SEIUSDT+3.20%PYTHUSDT-1.38%TIAUSDT+4.34%IMXUSDT+2.39%GRTUSDT-1.23%OPUSDT+4.95%WIFUSDT+0.12%IOTAUSDT+1.56%AXSUSDT+1.15%POLUSDT+1.93%FARTCOINUSDT-0.91%EOSUSDT-1.43%DYDXUSDT-0.84%GALAUSDT-5.72%ORDIUSDT-0.63%NOTUSDT-1.09%RONINUSDT+1.13%NVDA+0.14%AAPL-0.11%GOOGL+1.56%MSFT-0.11%AMZN-0.06%TSM+2.96%SPCX+7.35%META-0.06%AVGO+3.35%TSLA+0.21%SKHY+0.84%MU-0.46%BRK-B+0.43%LLY-0.61%AMD+2.95%JPM-0.24%WMT0.00%ASMLa+3.51%XOM+0.12%V+0.23%JNJ-1.02%INTC-0.56%0700.HK-0.02%MA+0.41%ABBV+1.11%1398.HK-0.23%CSCO+3.16%LRCX+2.17%AMAT+2.03%AP2d+2.88%CVX-0.20%ORCL+3.06%COST+0.62%CAT+2.31%BAC+0.04%DELL+3.82%KO-0.52%PG+0.67%UNH+1.83%0005.HK-0.11%ARM+5.18%HSBA.L+0.36%3988.HK-0.21%GE-0.91%1816.HK-28.01%MS+1.22%0857.HK-0.21%0939.HK-0.58%PM-0.38%1288.HK-0.58%GBPTRY+0.41%GBPHKD+0.32%GBPMXN-0.28%USDILS+0.16%USDCOP-0.04%GBPNZD0.00%GBPSGD0.00%GBPZAR0.00%EURSEK0.00%USDDKK0.00%GBPCHF0.00%GBPUSD0.00%GBPCAD0.00%USDPLN0.00%CHFNOK0.00%EURPLN0.00%PLNJPY0.00%NZDCAD0.00%NZDMXN0.00%EURCAD0.00%CHFJPY0.00%EURUSD0.00%EURJPY0.00%EURNZD0.00%GBPAUD0.00%EURNOK0.00%NZDCHF0.00%NZDSGD0.00%EURCZK0.00%NOKJPY0.00%AUDCAD0.00%CHFSGD0.00%SGDJPY0.00%AUDSGD0.00%NZDUSD0.00%GBPJPY0.00%EURGBP0.00%AUDNZD0.00%AUDJPY0.00%AUDUSD0.00%USDJPY0.00%USDCNH0.00%EURCHF0.00%USDMXN0.00%USDNOK0.00%USDTHB0.00%USDTRY0.00%USDSEK0.00%USDCAD0.00%USDCHF0.00%EURHKD0.00%EURAUD0.00%AUDNOK0.00%EURCNH0.00%EURZAR0.00%EURSGD0.00%AUDDKK0.00%CHFSEK0.00%AUDCHF0.00%USDSGD0.00%CADCHF0.00%NZDJPY0.00%EURDKK0.00%USDZAR0.00%USDHKD0.00%CADJPY0.00%GAGUSD0.00%XAGUSD0.00%HG10.00%S10.00%C10.00%XNGUSD0.00%USOIL0.00%W10.00%XAUUSD0.00%SUGAR0.00%COTTON0.00%COFFEE0.00%BTCUSD+0.37%ETHUSD+7.80%USDTUSD+0.01%XRPUSD+1.02%SOLUSD-0.22%TRXUSDT+0.25%ZECUSDT+0.50%DOGEUSD+0.81%XMRUSDT+1.87%LINKUSD+3.68%XLMUSD+0.04%BCHUSDT+2.11%UNIUSD+1.03%LTCUSD-4.30%SUIUSD+2.81%HBARUSDT-0.95%TONUSD+14.41%TAOUSDT+5.27%AAVEUSD+1.11%DOTUSDT+2.29%ICPUSDT+1.26%WLDUSDT+16.81%ONDOUSDT+0.69%ARBUSDT+2.74%JUPUSDT+4.21%ATOMUSDT+3.33%INJUSDT+1.48%STXUSDT+2.64%FETUSDT+2.06%SEIUSDT+3.20%PYTHUSDT-1.38%TIAUSDT+4.34%IMXUSDT+2.39%GRTUSDT-1.23%OPUSDT+4.95%WIFUSDT+0.12%IOTAUSDT+1.56%AXSUSDT+1.15%POLUSDT+1.93%FARTCOINUSDT-0.91%EOSUSDT-1.43%DYDXUSDT-0.84%GALAUSDT-5.72%ORDIUSDT-0.63%NOTUSDT-1.09%RONINUSDT+1.13%
IN

Incyte Corporation (INCY)

NASDAQ • Healthcare

$115.3
-$1.84 (-1.6%)
Market closed

Last close at October 2, 2026 at 20:00 UTC

Open$116.76
Day Range$114.57 - $117.19
Avg. Volume (3M)1.6M
Market Cap$23.3B
P/E Ratio14.2
52 Week Range
$82.82$132.6
Next EarningsIn 23 daysOct 27, 2026

Metrics Over Time

Where the Money Goes

Q2 2026
Revenueeverything earned$1.6B100%
Gross Profitminus cost of goods$1.5B94%
Operating Incomeminus R&D and overhead$697.8M42%
Net Incomeminus taxes and the rest$585.6M35%

In plain terms: out of every $100 in revenue, Incyte Corporation keeps $35 as net profit.

Fundamentals & Financials

Revenue (TTM)
$5.8B
Net Income (TTM)
$1.6B
EPS (TTM)
$8.13
ROA (TTM)
20.48%
Current Ratio
4.66

TTM is calculated as the sum of the four most recently completed quarters. This is a standard approach when monthly or real-time data is not available.

Earnings

-5.3%Q1 2026$1.8
+35.1%Q2 2026$1.81
+43.7%Q3 2026$3.09
Next

Oct 27

in 23 daysQ4 2026

% — EPS deviation from the forecast (beat / miss); quarters without a forecast show the reported EPS

Latest report — Q3 2026
Beat +43.7%

Incyte beat expectations on both the top and bottom line in the second fiscal quarter of 2026, reported July 28, with adjusted EPS of $3.09 topping the $2.15 estimate (+43.7%) and revenue of $1.674 billion topping the $1.504 billion estimate (+11.3%). Revenue rose ~38% to about $1.7 billion from roughly $1.2 billion a year ago, with the United States—by far the largest geography—up ~38% to around $1.6 billion, while Europe increased ~33% to about $105.1 million. Profitability remained elevated, with gross margin near 94% and operating margin around 42%, alongside operating income of roughly $697.9 million. Net income climbed ~45% to about $585.6 million from roughly $405.0 million a year earlier, while adjusted EPS was up ~97% from $1.57. The company generated operating cash flow of about $507.7 million in the quarter. For the next period, consensus calls for EPS of USD -3.31 on revenue of USD 1.472 billion.

Next report — what to expect

Incyte Corporation (INCY) is scheduled to report earnings on October 27, 2026. Wall Street’s next-period consensus calls for EPS of -$3.31 on revenue of $1.47 billion. For trailing context, revenue grew +37.7% year over year last quarter. Incyte has beaten EPS in 5 of its 8 most recent quarters.

View full earnings history

About Incyte Corporation

Incyte Corporation develops and markets prescription therapies in biotechnology, with revenue of $5.1 billion in FY2025. Listed on the NASDAQ as INCY, the company combines commercial oncology and hematology drugs with a clinical pipeline and global marketing operations built around therapies it develops itself.

Name
Incyte Corporation
CEO
William J. Meury
Industry
Healthcare
Year Founded
1991
Employees
2,844

Today's Snapshot

AI-generated

INCY closed 1.6% below yesterday's close, while its sector was flat. Trading was busier than usual, with volume about a quarter more than its usual level.

Trading Volume

Above 10d avg 1.6M

2.1M

vs S&P 500 Today

Underperforming Market

-2.35%

Updated: October 2, 2026 at 20:21 UTC

Technical Indicators

2 Buy1 Neutral5 Sell
INCY exhibits a bearish posture with the stock trading around $115 while momentum and trend indicators point to selling pressure. Short- and medium-term averages sit above the price, and MACD and CCI readings are negative, underscoring downward momentum even as stochastic measures show an early oversold bounce. ADX indicates a weak trend, and ATR reflects moderate volatility near 3%, while on-balance volume signals distribution. Classic pivot resistance sits above the market, reinforcing near-term supply. Technical takeaway: Downside-biased setup driven by negative momentum and selling volume despite oversold oscillators.
All signals
  • EMA (5 indicators)$109.43 - $122.79
    Sell
  • RSI (14)33.57
    Neutral
  • Stochastic %K (14, 3, 3)7.37
    Buy
  • MACD Level (12, 26)-1.17
    Sell
Stay Ahead of the Market

Get premium market insights delivered directly to your inbox.